BlackRock
VTVT icon

BlackRock’s vTv Therapeutics VTVT Stock Holding History

BlackRock’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$500K Buy
12,602
+1,996
+19% +$72.5K ﹤0.01% 4530
2025
Q4 		$424K Buy
10,606
+5,671
+115% +$158K ﹤0.01% 4519
2025
Q3 		$115K Buy
4,935
+108
+2% +$1.9K ﹤0.01% 4800
2025
Q2 		$72.4K Buy
4,827
+123
+3% +$2.25K ﹤0.01% 4912
2025
Q1 		$81.5K Sell
4,704
-69
-1% -$1.15K ﹤0.01% 4818
2024
Q4 		$65.9K Buy
4,773
+23
+0.5% +$340 ﹤0.01% 4884
2024
Q3 		$64.4K Buy
4,750
+3,653
+333% +$60.6K ﹤0.01% 4757
2024
Q2 		$19.4K Buy
1,097
+18
+2% +$429 ﹤0.01% 5012
2024
Q1 		$25.4K Sell
1,079
-262
-20% -$3.33K ﹤0.01% 4993
2023
Q4 		$15.4K Sell
1,341
-1
-0.1% -$14 ﹤0.01% 5113
2023
Q3 		$25.6K Sell
1,342
-36
-3% -$880 ﹤0.01% 5111
2023
Q2 		$40.8K Buy
1,378
+1
+0.1% +$32 ﹤0.01% 5099
2023
Q1 		$44.5K Sell
1,377
-4
-0.3% -$136 ﹤0.01% 5140
2022
Q4 		$36.6K Sell
1,381
-5
-0.4% -$165 ﹤0.01% 5284
2022
Q3 		$54K Sell
1,386
-7
-0.5% -$276 ﹤0.01% 5339
2022
Q2 		$42K Sell
1,393
-1,391
-50% -$35.7K ﹤0.01% 5446
2022
Q1 		$80K Sell
2,784
-65
-2% -$1.95K ﹤0.01% 5331
2021
Q4 		$113K Buy
2,849
+381
+15% +$20.5K ﹤0.01% 5240
2021
Q3 		$150K Buy
2,468
+21
+0.9% +$1.58K ﹤0.01% 5047
2021
Q2 		$224K Sell
2,447
-9,461
-79% -$958K ﹤0.01% 4879
2021
Q1 		$1.34M Buy
11,908
+900
+8% +$88.4K ﹤0.01% 4411
2020
Q4 		$818K Buy
11,008
+1,675
+18% +$128K ﹤0.01% 4261
2020
Q3 		$660K Buy
9,333
+1,105
+13% +$97.1K ﹤0.01% 4214
2020
Q2 		$741K Buy
8,228
+6,653
+422% +$657K ﹤0.01% 4127
2020
Q1 		$120K Sell
1,575
-18
-1% -$1.73K ﹤0.01% 4318
2019
Q4 		$109K Sell
1,593
-4
-0.3% -$243 ﹤0.01% 4435
2019
Q3 		$99K Sell
1,597
-29
-2% -$1.64K ﹤0.01% 4444
2019
Q2 		$93K Buy
1,626
+333
+26% +$20K ﹤0.01% 4485
2019
Q1 		$88K Sell
1,293
-16
-1% -$1.55K ﹤0.01% 4393
2018
Q4 		$140K Buy
1,309
+7
+0.5% +$648 ﹤0.01% 4292
2018
Q3 		$40K Buy
1,302
+21
+2% +$985 ﹤0.01% 4571
2018
Q2 		$79K Sell
1,281
-7,269
-85% -$537K ﹤0.01% 4495
2018
Q1 		$1.39M Sell
8,550
-58
-0.7% -$14.2K ﹤0.01% 3785
2017
Q4 		$2.07M Sell
8,608
-1,744
-17% -$391K ﹤0.01% 3686
2017
Q3 		$2.48M Buy
10,352
+68
+0.7% +$13.6K ﹤0.01% 3655
2017
Q2 		$2.04M Sell
10,284
-189
-2% -$39.4K ﹤0.01% 3677
2017
Q1 		$2.75M Buy
10,473
+10,470
+349,000% +$2.39M ﹤0.01% 3564
2016
Q4 		$1K Hold
3
– – ﹤0.01% 3706
2016
Q3 		$1K Hold
3
– – ﹤0.01% 3664
2016
Q2 		$1K Hold
3
– – ﹤0.01% 3693
2016
Q1 		$1K Buy
+3
New +$747 ﹤0.01% 3570

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock's VTVT Position: Q1 2026 in Review

BlackRock increased its vTv Therapeutics (VTVT) stake by 19% in Q1 2026, buying an estimated $72.5K and bringing the position to 12,602 shares worth $500K. The position accounts for ﹤0.01% of the portfolio, ranked #4530.

BlackRock first reported a position in VTVT in Q1 2016 and has held it in 41 quarters since. The position peaked at $2.75M in Q1 2017. 35 funds tracked by Wall St. Rank hold VTVT as of Q1 2026.

  • BlackRock held 12,602 shares of vTv Therapeutics worth $500K as of Q1 2026.
  • BlackRock bought 1,996 vTv Therapeutics shares in Q1 2026, an estimated $72.5K.
  • vTv Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4530 holding.
  • BlackRock first reported a position in vTv Therapeutics in Q1 2016 and has held it in 41 quarters since.
  • BlackRock's vTv Therapeutics position peaked at $2.75M in Q1 2017.
  • 35 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.